AveXis Inc (NASDAQ:AVXS) is set to post its quarterly earnings results after the market closes on Wednesday, August 9th. Analysts expect AveXis to post earnings of ($1.06) per share for the quarter.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, May 11th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.13. During the same quarter in the prior year, the firm posted ($1.24) earnings per share. On average, analysts expect AveXis to post $-4.27 EPS for the current fiscal year and $-4.27 EPS for the next fiscal year.

Shares of AveXis Inc (NASDAQ AVXS) opened at 97.05 on Tuesday. The stock’s market capitalization is $2.70 billion. The firm has a 50-day moving average price of $80.67 and a 200-day moving average price of $71.89. AveXis Inc has a 1-year low of $31.55 and a 1-year high of $97.77.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/08/avexis-inc-avxs-set-to-announce-earnings-on-wednesday.html.

Several research analysts recently commented on the company. Jefferies Group LLC reissued a “buy” rating and set a $92.00 target price on shares of AveXis in a research note on Wednesday, April 19th. Chardan Capital set a $103.00 price objective on AveXis and gave the stock a “buy” rating in a research report on Sunday, June 18th. Sanford C. Bernstein assumed coverage on AveXis in a research report on Thursday, July 27th. They set an “outperform” rating and a $108.00 price objective for the company. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Finally, Citigroup Inc. assumed coverage on AveXis in a research report on Tuesday, May 23rd. They set a “buy” rating and a $90.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $93.60.

In other news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $81.88, for a total transaction of $145,746.40. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $145,746.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 5,340 shares of company stock valued at $434,872. Insiders own 18.60% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Earnings History for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.